Callahan Advisors LLC Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Callahan Advisors LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.1% in the 3rd quarter, Holdings Channel reports. The firm owned 3,125 shares of the biopharmaceutical company’s stock after selling 994 shares during the period. Callahan Advisors LLC’s holdings in Gilead Sciences were worth $262,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Gilead Sciences by 198.3% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Cedar Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 160 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,847 shares of company stock worth $3,033,340. 0.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Truist Financial upped their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price objective on shares of Gilead Sciences in a research note on Tuesday, October 29th. Finally, Barclays upped their price objective on Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $86.85.

Gilead Sciences Stock Performance

GILD opened at $90.22 on Wednesday. The stock has a market cap of $112.32 billion, a P/E ratio of 110.02, a P/E/G ratio of 3.12 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The stock’s 50 day simple moving average is $84.32 and its 200 day simple moving average is $74.55. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $90.71.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.